Over the past two months, Beckman Coulter has released its Vidiera NsD nucleic sample detection platform and Vidiera NsP nucleic sample preparation platform. The new instruments are key to the firm's emerging efforts in the molecular diagnostics field. The NsD platform is based on Beckman's capillary electrophoresis technology and was launched last month in the US, with an international roll-out planned for next year. The launch of the NsP, which is based on Beckman's primary tube-handling technology and Biomek automation, was announced last week.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.